Medicinova Inc (MNOV)
MNOV trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1226616/000119312526100432/0001193125-26-100432-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MNOV on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001226616 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $410K |
| Net income | -$12.0M |
| Operating income | -$13.3M |
| Net margin | -2928.8% |
| Operating margin | -3242.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $30.8M |
| Total assets | $45.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 167.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $29.3M cash; operating cash flow -$2.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,232,668 (2026-11-10); 49,046,246 a year earlier; 49,046,246 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $139K | -$2.8M | -$2.4M | $29.3M | No debt tags | $936K | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $458K | -$2.3M | -$1.9M | $25.4M | No debt tags | $920K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $187K | -$2.6M | -$3.5M | $27.3M | No debt tags | $597K | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $152K | -$2.8M | -$2.0M | $30.8M | No debt tags | $410K | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $123K | -$3.1M | -$1.7M | $32.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $135K | -$3.3M | -$2.3M | $34.3M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$2.9M | -$3.8M | $36.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$2.8M | -$1.9M | $40.4M | No debt tags | Needs four quarters | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-30 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 881 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.1% |
| 1 month | -6.7% |
| 3 months | +6.9% |
| Year to date | +6.9% |
| 1 year | -9.1% |
| From 52-week high | -59.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| TENX | Tenax Therapeutics Inc. | $1.48 | -8.64% | $67.4M |
| GOSS | Gossamer Bio Inc. | $10.98 | +0.09% | $67.2M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $0.5762 | +1.11% | $73.3M |
| KALA | KALA BIO Inc. | $3.83 | -8.02% | $74.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier